Community-acquired pneumonia causes great mortality and morbidity and high costs
worldwide. Empirical selection of antibiotic treatment is the cornerstone of management of …

Azithromycin is a macrolide antibiotic which inhibits bacterial protein synthesis, quorum-
sensing and reduces the formation of biofilm. Accumulating effectively in cells, particularly …

While the world is grappling with the consequences of a global pandemic related to SARS-
CoV-2 causing severe pneumonia, available evidence points to bacterial infection with …

Importance The clinical benefit of adding a macrolide to a β-lactam for empirical treatment of
moderately severe community-acquired pneumonia remains controversial. Objective To test …

Objective: Some studies suggest better outcomes with macrolide therapy for critically ill
patients with community-acquired pneumonia. To further explore this, we performed a …

Importance Although clinical practice guidelines recommend combination therapy with
macrolides, including azithromycin, as first-line therapy for patients hospitalized with …

Severe Community-Acquired Pneumonia - Critical Care Clinics Skip to Main Content
Advertisement Critical Care Clinics Log in Register Log in Subscribe Claim Skip menu …

Community‐acquired pneumonia (CAP) remains a leading cause of morbidity and mortality
among the infectious diseases. Despite the implementation of national pneumococcal …

The FDA recently approved labeling changes advising against the use of azithromycin in
patients with known cardiovascular risk factors such as QT-interval prolongation …

Background Addition of macrolide antibiotics to β-lactam antibiotics for the treatment of
patients in hospital with community-acquired pneumonia is based on results from …